Thomas Frazier is professor of psychology at John Carroll University in University Heights, Ohio.
Thomas Frazier
Professor of psychology
John Carroll University
From this contributor
Tempering tales of a new autism measure: A conversation with Thomas Frazier
The questionnaire, designed to screen children for autism, isn’t ready for clinical use without further validation, contrary to what some overblown newspaper headlines reported.
Tempering tales of a new autism measure: A conversation with Thomas Frazier
In search of ‘social’ subtypes of autism
Grouping autistic people based on their social abilities may reveal subtypes of the condition.
In search of ‘social’ subtypes of autism
Studies of gaze could improve diagnosis, treatment of autism
Understanding how gaze differs in autistic people may help improve their lives.
Studies of gaze could improve diagnosis, treatment of autism
Navigating autism’s gender gap
The number of people in a study, the proportion of male and female participants, and many other factors can affect research on sex differences in autism, says Thomas Frazier.
Explore more from The Transmitter
Supported by a $40 million NIH grant, Yale brain shuttle technology raises questions
Yale University claims its STEP platform might be able to deliver gene-editing tools into the brain via multiple routes. Researchers are eager to see more.
Supported by a $40 million NIH grant, Yale brain shuttle technology raises questions
Yale University claims its STEP platform might be able to deliver gene-editing tools into the brain via multiple routes. Researchers are eager to see more.
What counts as a ‘naturalistic’ behavior?
Nedah Nemati explains how neuroscience methods and the lived experience of the scientists themselves shape how we define the behaviors we seek to explain.
What counts as a ‘naturalistic’ behavior?
Nedah Nemati explains how neuroscience methods and the lived experience of the scientists themselves shape how we define the behaviors we seek to explain.
Allen Institute sets sights on treatments for five brain diseases
The Brain Health Accelerator program aims to harness single-cell transcriptomics and cell-type-specific genetic tools to develop treatments for Alzheimer’s, Huntington’s and Parkinson’s diseases, Lewy body dementia and ALS.
Allen Institute sets sights on treatments for five brain diseases
The Brain Health Accelerator program aims to harness single-cell transcriptomics and cell-type-specific genetic tools to develop treatments for Alzheimer’s, Huntington’s and Parkinson’s diseases, Lewy body dementia and ALS.